Adma Biologics (ADMA) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $36.4 million.
- Adma Biologics' Consolidated Net Income rose 144.53% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.4 million, marking a year-over-year increase of 20741.36%. This contributed to the annual value of $197.7 million for FY2024, which is 80000.0% up from last year.
- Per Adma Biologics' latest filing, its Consolidated Net Income stood at $36.4 million for Q3 2025, which was up 144.53% from $34.2 million recorded in Q2 2025.
- In the past 5 years, Adma Biologics' Consolidated Net Income registered a high of $111.9 million during Q4 2024, and its lowest value of -$18.8 million during Q2 2021.
- Its 5-year average for Consolidated Net Income is $7.2 million, with a median of -$6.8 million in 2023.
- As far as peak fluctuations go, Adma Biologics' Consolidated Net Income plummeted by 4962.75% in 2023, and later surged by 129996.1% in 2024.
- Quarter analysis of 5 years shows Adma Biologics' Consolidated Net Income stood at -$16.5 million in 2021, then increased by 28.55% to -$11.8 million in 2022, then plummeted by 49.63% to -$17.6 million in 2023, then soared by 734.15% to $111.9 million in 2024, then tumbled by 67.44% to $36.4 million in 2025.
- Its Consolidated Net Income stands at $36.4 million for Q3 2025, versus $34.2 million for Q2 2025 and $26.9 million for Q1 2025.